TELZIR TABLET

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

FOSAMPRENAVIR (FOSAMPRENAVIR CALCIUM)

Beschikbaar vanaf:

VIIV HEALTHCARE ULC

ATC-code:

J05AE07

INN (Algemene Internationale Benaming):

FOSAMPRENAVIR

Dosering:

700MG

farmaceutische vorm:

TABLET

Samenstelling:

FOSAMPRENAVIR (FOSAMPRENAVIR CALCIUM) 700MG

Toedieningsweg:

ORAL

Eenheden in pakket:

60

Prescription-type:

Prescription

Therapeutisch gebied:

HIV PROTEASE INHIBITORS

Product samenvatting:

Active ingredient group (AIG) number: 0150429001; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2009-12-08

Productkenmerken

_ _
_Page 1 of 55_
PRODUCT MONOGRAPH
PR
TELZIR
Fosamprenavir tablets 700 mg
(as fosamprenavir calcium)
Fosamprenavir oral suspension 50 mg/mL
(as fosamprenavir calcium)
Antiretroviral Agent
ViiV Healthcare ULC
245, boulevard Armand-Frappier
Laval, Quebec
H7V 4A7
Date of Revision:
July 5, 2019
Submission Control No.: 226294
© 2019 ViiV Healthcare group of companies or its licensor.
Trademarks are owned by or licensed to the ViiV Healthcare group of
companies.
_ _
_Page 2 of 55_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................6
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................28
OVERDOSAGE
................................................................................................................30
ACTION AND CLINICAL PHARMACOLOGY
............................................................30
STORAGE AND STABILITY
..........................................................................................34
SPECIAL HANDLING INSTRUCTIONS
.......................................................................34
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................34
PART II: SCIENTIFIC INFORMATION
...............................................................................36
PHARMACEUTICAL INFORM